Endothelial progenitor dysfunction in the pathogenesis of diabetic retinopathy: Treatment concept to correct diabetes-associated deficits

EPMA Journal

Volumn 1, Issue 1, 2010, Pages 88-100

  Calzi, Sergio Li ^a   Neu, Matthew B ^a   Shaw, Lynn C ^a   Grant, Maria B ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adult stem cells; Angiogenesis; Diabetic retinopathy; Endothelial progenitor cells; Ischemia targeted treatment

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE;

ARTICLE; BONE MARROW CELL; CELL CULTURE; CLINICAL EFFECTIVENESS; CYTOLOGY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA DEGENERATION; RETINA ISCHEMIA; RETINA NEOVASCULARIZATION; STEM CELL NICHE; THERAPY EFFECT; TREATMENT PLANNING;

EID: 79960049458     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0011-8     Document Type: Article

References (106)

1. Fong DS, Sharza M, Chen W, et al. Vision loss among diabetics in a group model Health Maintenance Organization (HMO). Am J Ophthalmol. 2002;133:236-41.
2. ETDRS. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98:766-85.
3. ETDRS. Focal photocoagulation treatment of diabetic macular edema. ETDRS Report Number 19. Arch Ophthalmol. 1995;113:1144-55.
4. Avery RB, Diener-West M, Reynolds SM, et al. Histopathologic characteristics of choroidal melanoma in eyes enucleated after iodine 125 brachytherapy in the collaborative ocular melanoma study. Arch Ophthalmol. 2008;126:207-12.
5. Domen J, Wagers A, Weissman IL. Bone Marrow (hematiopoietic) Stem Cells [Online]. 2006.
6. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/ progenitor cell principals. Blood. 2007;109:1801-9.
7. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-7.
8. Schatteman GC, Dunnwald M, Jiao C. Biology of bone marrowderived endothelial cell precursors. Am J Physiol Heart Circ Physiol. 2007;292:H1-18.
9. Spring H, Schuler T, Arnold B, et al. Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci U S A. 2005;102:18111-6.
10. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol. 2006;6:93-106.
11. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003;9:702-12.
12. Minami E, Laflamme MA, Saffitz JE, et al. Extracardiac progenitor cells repopulate most major cell types in the transplanted human heart. Circulation. 2005;112:2951-8.
13. Ruzinova MB, Schoer RA, Gerald W, et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell. 2003;4:277-89.
14. Peters BA, Diaz LA, Polyak K, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005;11:261-2.
15. Caballero S, Sengupta N, Afzal A, et al. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes. 2007;56:960-7.
16. Grant MB, May WS, Caballero S, et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med. 2002;8:607-12.
17. Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998;92:362-7.
18. Fernandez Pujol B, Lucibello FC, Gehling UM, et al. Endothelial-like cells derived from human CD14 positive monocytes. Differentiation. 2000;65:287-300.
19. Eggermann J, Kliche S, Jarmy G, et al. Endothelial progenitor cell culture and differentiation in vitro: a methodological comparison using human umbilical cord blood. Cardiovasc Res. 2003;58:478-86.
20. Delorme B, Basire A, Gentile C, et al. Presence of endothelial progenitor cells, distinct from mature endothelial cells, within human CD146+ blood cells. Thromb Haemost. 2005;94:1270-9.
21. Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004;24:288-93.
22. Gehling UM, Ergun S, Schumacher U, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood. 2000;95:3106-12.
23. Gulati R, Jevremovic D, Peterson TE, et al. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circ Res. 2003;93:1023-5.
24. Crosby JR, Kaminski WE, Schatteman G, et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res. 2000;87:728-30.
25. Yoon CH, Hur J, Park KW, et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation. 2005;112:1618-27.
26. Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res. 2000;86:1198-202.
27. Harraz M, Jiao C, Hanlon HD, et al. CD34- blood-derived human endothelial cell progenitors. Stem Cells. 2001;19:304-12.
28. Rohde E, Malischnik C, Thaler D, et al. Blood monocytes mimic endothelial progenitor cells. Stem Cells. 2006;24:357-67.
29. Schmeisser A, Strasser RH. Phenotypic overlap between hematopoietic cells with suggested angioblastic potential and vascular endothelial cells. J Hematother Stem Cell Res. 2002;11:69-79.
30. Schmeisser A, Garlichs CD, Zhang H, et al. Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc Res. 2001;49:671-80.
31. Romagnani P, Annunziato F, Liotta F, et al. CD14+CD34low cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors. Circ Res. 2005;97:314-22.
32. George J, Herz I, Goldstein E, et al. Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol. 2003;23:e57-60.
33. Ghani U, Shuaib A, Salam A, et al. Endothelial progenitor cells during cerebrovascular disease. Stroke. 2005;36:151-3.
34. Loomans CJ, Wan H, de Crom R, et al. Angiogenic murine endothelial progenitor cells are derived from a myeloid bone marrow fraction and can be identified by endothelial NO synthase expression. Arterioscler Thromb Vasc Biol. 2006;26:1760-7.
35. Case J, Mead LE, Bessler WK, et al. Human CD34+ AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol. 2007;35:1109-18.
36. Loomans CJ, van Haperen R, Duijs JM, et al. Differentiation of bone marrow-derived endothelial progenitor cells is shifted into a proinflammatory phenotype by hyperglycemia. Mol Med. 2009;15:152-9.
37. Donato AJ, Eskurza I, Silver AE, et al. Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium-dependent dilation and upregulation of nuclear factor-kappaB. Circ Res. 2007;100:1659-66.
38. Imanishi T, Hano T, Sawamura T, et al. Oxidized low-density lipoprotein induces endothelial progenitor cell senescence, leading to cellular dysfunction. Clin Exp Pharmacol Physiol. 2004;31:407-13.
39. Loomans CJ, de Koning EJ, Staal FJ, et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes. 2004;53:195-9.
40. Zhu J, Xu ZK, Miao Y, et al. Changes of inducible protein-10 and regulated upon activation, normal T cell expressed and secreted protein in acute rejection of pancreas transplantation in rats. World J Gastroenterol. 2006;12:4156-60.
41. Tamarat R, Silvestre JS, Le Ricousse-Roussanne S, et al. Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. Am J Pathol. 2004;164:457-66.
42. Kielczewski JL, Jarajapu YP, McFarland EL, et al. Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circ Res. 2009;105:897-905.
43. Ma FX, Zhou B, Chen Z, et al. Oxidized low density lipoprotein impairs endothelial progenitor cells by regulation of endothelial nitric oxide synthase. J Lipid Res. 2006;47:1227-37.
44. Sobrevia L, Mann GE. Dysfunction of the endothelial nitric oxide signalling pathway in diabetes and hyperglycaemia. Exp Physiol. 1997;82:423-52.
45. Weyrich AS, Ma XL, Lefer AM. The role of L-arginine in ameliorating reperfusion injury after myocardial ischemia in the cat. Circulation. 1992;86:279-88.
46. Kaesemeyer WH, Ogonowski AA, Jin L, et al. Endothelial nitric oxide synthase is a site of superoxide synthesis in endothelial cells treated with glyceryl trinitrate. Br J Pharmacol. 2000; 131:1019-23.
47. Berkowitz DE, White R, Li D, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation. 2003;108:2000-6.
48. Jean C, Fromentin G, Tome D, et al. Wistar rats allowed to selfselect macronutrients from weaning to maturity choose a highprotein, high-lipid diet. Physiol Behav. 2002;76:65-73.
49. Ellis EA, Guberski DL, Hutson B, et al. Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/WOR rat. Nitric Oxide. 2002;6:295-304.
50. Camici GG, Schiavoni M, Francia P, et al. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci U S A. 2007;104:5217-22.
51. Kobayashi T, Taguchi K, Takenouchi Y, et al. Insulin-induced impairment via peroxynitrite production of endotheliumdependent relaxation and sarco/endoplasmic reticulum Ca(2+)- ATPase function in aortas from diabetic rats. Free Radic Biol Med. 2007;43:431-43.
52. Szabo C, Mabley JG, Moeller SM, et al. Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med. 2002;8:571-80.
53. Munzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995;95:187-94.
54. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest. 1991;87:432-8.
55. Leal EC, Manivannan A, Hosoya K, et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2007;48:5257-65.
56. Stadler K, Bonini MG, Dallas S, et al. Direct evidence of iNOSmediated in vivo free radical production and protein oxidation in acetone-induced ketosis. Am J Physiol Endocrinol Metab. 2008;295:E456-62.
57. Cheng X, Cheng XS, Kuo KH, et al. Inhibition of iNOS augments cardiovascular action of noradrenaline in streptozotocin-induced diabetes. Cardiovasc Res. 2004;64:298-307.
58. Nagareddy PR, Xia Z, McNeill JH, et al. Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocininduced diabetes. Am J Physiol Heart Circ Physiol. 2005;289:H2144-52.
59. Aicher A, Zeiher AM, Dimmeler S. Mobilizing endothelial progenitor cells. Hypertension. 2005;45:321-5.
60. Heissig B, Werb Z, Rafii S, et al. Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb Haemost. 2003;90:570-6.
61. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002;109:625-37.
62. Shintani S, Murohara T, Ikeda H, et al. Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation. 2001;103:897-903.
63. Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt- dependent phosphorylation. Nature. 1999;399:601-5.
64. Sorrentino SA, Bahlmann FH, Besler C, et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptorgamma agonist rosiglitazone. Circulation. 2007;116:163-73.
65. Thum T, Fraccarollo D, Schultheiss M, et al. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes. 2007; 56:666-74.
66. Vasa M, Breitschopf K, Zeiher AM, et al. Nitric oxide activates telomerase and delays endothelial cell senescence. Circ Res. 2000;87:540-2.
67. Li Calzi S, Purich DL, Hee Chang K, et al. Carbon monoxide and nitric oxide mediate cytoskeletal reorganization in microvascular cells via Vasodilator-Stimulated Phosphoprotein (VASP) phosphorylation: evidence for blunted responsiveness in diabetes. Diabetes. 2008.
68. Segal MS, Shah R, Afzal A, et al. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes. 2006;55:102-9.
69. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 2006;124:175-89.
70. Jarajapu YP, Thampi P, Caballero S, et al. Differential Paracrine Dysfunction and Hypoxic Desensitization in Diabetic CD34+ and CD14+ Bone Marrow Derived Cells (BMDC). Circulation. 2009;120:S1124.
71. Gao J, Zhao WX, Zhou LJ, et al. Protective effects of propofol on lipopolysaccharide-activated endothelial cell barrier dysfunction. Inflamm Res. 2006;55:385-92.
72. Luo T, Xia Z, Ansley DM, et al. Propofol dose-dependently reduces tumor necrosis factor-alpha-Induced human umbilical vein endothelial cell apoptosis: effects on Bcl-2 and Bax expression and nitric oxide generation. Anesth Analg. 2005;100:1653-9.
73. Chen YS, Chen KH, Liu CC, et al. Propofol-induced vascular permeability change is related to the nitric oxide signaling pathway and occludin phosphorylation. J Biomed Sci. 2007;14:629-36.
74. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108:391-7.
75. Landmesser U, Engberding N, Bahlmann FH, et al. Statininduced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation. 2004;110:1933-9.
76. Verma S, Szmitko PE, Anderson TJ. Endothelial function: ready for prime time? Can J Cardiol. 2004;20:1335-9.
77. Thum T, Fraccarollo D, Galuppo P, et al. Bone marrow molecular alterations after myocardial infarction: Impact on endothelial progenitor cells. Cardiovasc Res. 2006;70:50-60.
78. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23:1455-9.
79. Dayoub H, Achan V, Adimoolam S, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation. 2003;108:3042-7.
80. Busik J, Tikhonenko M, Bhatwadekar A, et al. Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. J Exp Med. Epub ahead of time. 2009.
81. Naveiras O, Nardi V, Wenzel PL, et al. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature. 2009.
82. Berria R, Glass L, Mahankali A, et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in type II diabetes mellitus. Clin Pharmacol Ther. 2007;82:275-81.
83. Digman C, Borto D, Nasraway Jr SA. Hyperglycemia in the critically ill. Nutr Clin Care. 2005;8:93-101.
84. Maaravi Y, Stessman J. Mild, reversible pancytopenia induced by rosiglitazone. Diabetes Care. 2005;28:1536.
85. Lazarenko OP, Rzonca SO, Hogue WR, et al. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology. 2007;148:2669-80.
86. Corre J, Barreau C, Cousin B, et al. Human subcutaneous adipose cells support complete differentiation but not self-renewal of hematopoietic progenitors. J Cell Physiol. 2006;208:282-8.
87. Nishikawa S, Kumar PK, Jeoung YH, et al. Chemical probing studies of the hepatitis delta virus (HDV) genomic ribozyme. Nucleic Acids Symp Ser. 1993:119-20.
88. Belaid-Choucair Z, Lepelletier Y, Poncin G, et al. Human bone marrow adipocytes block granulopoiesis through neuropilin-1- induced granulocyte colony-stimulating factor inhibition. Stem Cells. 2008;26:1556-64.
89. Miharada K, Hiroyama T, Sudo K, et al. Lipocalin 2-mediated growth suppression is evident in human erythroid and monocyte/ macrophage lineage cells. J Cell Physiol. 2008;215:526-37.
90. Yan QW, Yang Q, Mody N, et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes. 2007;56:2533-40.
91. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000;96:1723-32.
92. Zhang Y, Harada A, Bluethmann H, et al. Tumor necrosis factor (TNF) is a physiologic regulator of hematopoietic progenitor cells: increase of early hematopoietic progenitor cells in TNF receptor p55- deficient mice in vivo and potent inhibition of progenitor cell proliferation by TNF alpha in vitro. Blood. 1995; 86:2930-7.
93. DiMascio L, Voermans C, Uqoezwa M, et al. Identification of adiponectin as a novel hemopoietic stem cell growth factor. J Immunol. 2007;178:3511-20.
94. Awad O, Jiao C, Ma N, et al. Obese diabetic mouse environment differentially affects primitive and monocytic endothelial cell progenitors. Stem Cells. 2005;23:575-83.
95. Klein R, Knudtson MD, Lee KE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115:1859-68.
96. Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005;45:1449-57.
97. Kusuyama T, Omura T, Nishiya D, et al. Effects of treatment for diabetes mellitus on circulating vascular progenitor cells. J Pharmacol Sci. 2006;102:96-102.
98. Lee IG, Chae SL, Kim JC. Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy. Eye (Lond). 2006;20:546-52.
99. Brunner S, Schernthaner GH, Satler M, et al. Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy: first in vivo data. Invest Ophthalmol Vis Sci. 2009;50:392-8.
100. Otani A, Kinder K, Ewalt K, et al. Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med. 2002;8:1004-10.
101. Dorrell MI, Otani A, Aguilar E, et al. Adult bone marrow-derived stem cells use R-cadherin to target sites of neovascularization in the developing retina. Blood. 2004;103:3420-7.
102. Dorrell MI, Friedlander M. Mechanisms of endothelial cell guidance and vascular patterning in the developing mouse retina. Prog Retin Eye Res. 2006;25:277-95.
103. Thill M, Strunnikova NV, Berna MJ, et al. Late outgrowth endothelial progenitor cells in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:2696-708.
104. Livrea MA, Tesoriere L, Pintaudi AM, et al. Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood. 1996;88:3608-14.
105. van Beem RT, Nur E, Zwaginga JJ, et al. Elevated endothelial progenitor cells during painful sickle cell crisis. Exp Hematol. 2009;37:1054-9.
106. Schachinger V, Erbs S, Elsasser A, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27:2775-83.